Michelangelo Maestri
Overview
Explore the profile of Michelangelo Maestri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
80
Citations
861
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nicoli V, Giangreco M, Pardini E, Petrini I, Bacchin D, Aprile V, et al.
Epigenomics
. 2024 Nov;
16(21-22):1337-1350.
PMID: 39513235
To investigate DNA methylation levels of a panel of genes in thymic epithelial tumors (TETs). We selected 15 genes among the most promising epigenetic biomarkers of TETs and evaluated their...
2.
Hoxhaj D, Pascazio A, Maestri M, Ricci G, Fabbrini M, Torresi F, et al.
Front Neurol
. 2024 Jul;
15:1389949.
PMID: 39011358
Introduction: Excessive daytime sleepiness (EDS) is a common and debilitating symptom in both forms of myotonic dystrophy (DM), significantly impacting patients' quality of life. The review focuses on the purpose...
3.
Koneczny I, Mane-Damas M, Zong S, de Haas S, Huda S, van Kruining D, et al.
Front Immunol
. 2024 May;
15:1325171.
PMID: 38715598
Introduction: Muscle-specific kinase (MuSK)- myasthenia gravis (MG) is caused by pathogenic autoantibodies against MuSK that correlate with disease severity and are predominantly of the IgG4 subclass. The first-line treatment for...
4.
Sechi E, Deiana G, Puci M, Zara P, Ortu E, Porcu C, et al.
Muscle Nerve
. 2024 Mar;
69(5):637-642.
PMID: 38456240
Introduction/aims: The global incidence and prevalence of myasthenia gravis (MG) range between 6-31/million and 10-37/100,000, respectively. Sardinia is a high-risk region for different immune-mediated disorders, but the epidemiology of MG...
5.
Sicolo E, Zirafa C, Romano G, Brandolini J, De Palma A, Bongiolatti S, et al.
Cancers (Basel)
. 2024 Jan;
16(2).
PMID: 38254894
Thymectomy is the gold standard in the treatment of thymic neoplasm and plays a key role in the therapeutic path of myasthenia gravis. For years, sternotomy has been the traditional...
6.
Pardini E, Cucchiara F, Palumbo S, Tarrini G, Di Vita A, Coppede F, et al.
Front Oncol
. 2023 Sep;
13:1224491.
PMID: 37671056
Background: Thymic epithelial tumors are rare malignant neoplasms that are frequently associated with paraneoplastic syndromes, especially myasthenia gravis. GTF2I is an oncogene mutated in a subgroup of thymomas that is...
7.
Pascazio A, Maestri M, Pasquali L, Hoxhaj D, Fabbrini M, Furfori G, et al.
Mult Scler Relat Disord
. 2023 Aug;
79:104946.
PMID: 37639779
Background: Restless Legs Syndrome is a sleep-related sensorimotor disorder with a higher prevalence in Multiple Sclerosis (MS) patients than in the general population. Our aim was to determine the prevalence...
8.
Castelnovo A, Miano S, Ferri R, Raggi A, Maestri M, Bottasini V, et al.
Brain Sci
. 2023 Mar;
13(3).
PMID: 36979185
Benzodiazepine (BDZ) misuse is a growing health problem, with 1-2% of patients under BDZ treatment meeting the criteria for use disorder or dependence. Although BDZ addiction potential has been known...
9.
Puligheddu M, Figorilli M, Antelmi E, Arnaldi D, Casaglia E, dAloja E, et al.
Neurol Sci
. 2022 Nov;
44(2):783.
PMID: 36342551
No abstract available.
10.
Puligheddu M, Figorilli M, Antelmi E, Arnaldi D, Casaglia E, dAloja E, et al.
Neurol Sci
. 2022 Sep;
43(12):6919-6928.
PMID: 36087148
Most patients with idiopathic REM sleep behavior disorder (iRBD) will develop an overt α-synucleinopathy over time, with a rate of phenoconversion of 73.5% after 12 years from diagnosis. Several markers...